Granted Patent
B2
US 12,441,994 · App. 18/526,758 · Granted Oct 14, 2025
Methods for targeted insertion of DNA in genes
Assignee:
BLUEALLELE CORPORATION
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases and transposases. The methods and compositions described herein can be used to modify the coding sequence of endogenous genes.
Claims (25)
1. A vector comprising a transgene comprising in 5′ to 3′ orientation: a first splice acceptor, a first coding sequence, a first terminator, a second terminator reverse complement, a second coding sequence reverse complement, and a second splice acceptor reverse complement,
wherein the first coding sequence is operably linked to the first splice acceptor and first terminator, and the second coding sequence is operably linked to the second splice acceptor and second terminator, wherein the first terminator is selected from an SV40 poly (A) or BGH poly (A),
wherein the first and second coding sequences differ in nucleic acid sequence but each encode the same amino acid sequence, wherein said amino acid sequences encoded by the first and second coding sequences correspond to amino acid sequences having at least 80% identity to the amino acid sequence of an endogenous human ATXN3 gene, and wherein the transgene is equal to or less than 4.7 kb.
2. The vector of claim 1 , wherein the second terminator is selected from an SV40 poly (A) or BGH poly (A).
3. The vector of claim 2 , wherein the amino acid sequences encoded by the first and second coding sequences have at 100% sequence identity to the amino acid sequence encoded by the endogenous ATXN3 gene.
4. The vector of claim 1 , wherein the amino acid sequences encoded by the first and second coding sequences have 98% sequence identity to the amino acid sequence encoded by the endogenous ATXN3 gene.
5. The vector of claim 1 , wherein the amino acid sequence encoded by the first and second coding sequences have 99% sequence identity to the amino acids encoded by the endogenous ATXN3 gene.
6. The vector of claim 3 , wherein the vector a viral vector.
7. The vector of claim 6 , wherein the viral vector is selected from the group consisting of an adenovirus vector and a lentivirus vector.
8. The vector of claim 7 , wherein the viral vector is incorporated into a viral particle.
9. The of vector claim 8 , wherein the transgene does not comprise homology arms.
10. The vector of claim 9 , wherein the first splice acceptor comprises a splice acceptor sequence from an intron of the endogenous ATXN3 gene.
11. An adeno-associated viral vector comprising:
(i) a transgene comprising from 5′ to 3′ orientation a first splice acceptor, a first coding sequence, a first terminator, a second terminator reverse complement, a second coding sequence reverse complement, and a second splice acceptor reverse complement,
wherein the first coding sequence is operably linked to the first splice acceptor and first terminator, and the second coding sequence is operably linked to the second splice acceptor and second terminator, wherein the first terminator is selected from an SV40 poly (A) or BGH poly (A),
wherein the first and second coding sequences differ in nucleic acid sequence but each encode the same amino acid sequence, wherein said amino acids encoded by the first and second coding sequences correspond to amino acid sequences having at least 80% identity to the amino acid sequence of an endogenous human ATXN3 gene, and wherein the transgene is equal to or less than 4.7 kb; and
(ii) adeno-associated virus inverted terminal repeats flanking the transgene.
12. The adeno-associated viral vector of claim 11 , wherein the first and second coding sequences encode amino acid sequences having 100% sequence identity to the amino acid sequence encoded by the endogenous ATXN3 gene.
13. The adeno-associated viral vector of claim 11 , wherein the amino acids encoded by the first and second coding sequences having 98% sequence identity to the amino acids encoded by the endogenous ATXN3 gene.
14. The adeno-associated viral vector of claim 12 , wherein the amino acids encoded by the first and second coding sequences having 99% sequence identity to the amino acids encoded by the endogenous ATXN3 gene.
15. The adeno-associated viral vector of claim 11 , wherein the second terminator is selected from an SV40 poly (A) or BGH poly (A).
16. The adeno-associated viral vector of claim 15 , wherein the viral vector is incorporated into a viral particle.
17. The adeno-associated viral vector of claim 15 , wherein the transgene does not comprise homology arms.
18. The adeno-associated viral vector of claim 17 , wherein the first splice acceptor comprises splice acceptor sequence from an intron of the endogenous ATXN3 gene.
19. The adeno-associated viral vector of claim 17 , wherein the first terminator is an SV40 poly (A) and the second terminator is a BGH poly (A).
Continuity (9)
Provisional Application
62864432
· Jun 20, 2019
Provisional Application
62830654
· Apr 8, 2019
Provisional Application
62746497
· Oct 16, 2018
References Cited (367)
US 6228639B1
· Gaitanaris
· 2001
[cited by applicant]
US 6740503B1
· Harrington et al.
· 2004
[cited by applicant]
US 7005299B1
· Smith et al.
· 2006
[cited by applicant]
US 9255250B2
· Gregory et al.
· 2016
[cited by applicant]
US 9493827B2
· Von Kalle et al.
· 2016
[cited by applicant]
US 9677070B2
· Allison et al.
· 2017
[cited by applicant]
US 9765404B2
· Sastry-Dent et al.
· 2017
[cited by applicant]
US 9873894B2
· Conway et al.
· 2018
[cited by applicant]
US 9877988B2
· Rebar
· 2018
[cited by applicant]
US 20040106566A1
· Lin et al.
· 2004
[cited by applicant]
US 20130280222A1
· Kay et al.
· 2013
[cited by applicant]
US 20160040155A1
· Maizels et al.
· 2016
[cited by applicant]
US 20160281111A1
· Cotta-Ramusino et al.
· 2016
[cited by applicant]
US 20180110877A1
· Wilson et al.
· 2018
[cited by applicant]
US 20180112213A1
· Welstead et al.
· 2018
[cited by applicant]
US 20180119123A1
· Gori et al.
· 2018
[cited by applicant]
US 20180362590A1
· Monds et al.
· 2018
[cited by applicant]
US 20190032156A1
· Gong et al.
· 2019
[cited by applicant]
US 20190134221A1
· Bumcrot et al.
· 2019
[cited by applicant]
US 20190276850A1
· Brinkmann et al.
· 2019
[cited by applicant]
US 20190330603A1
· Ahlfors et al.
· 2019
[cited by applicant]
US 20200231974A1
· Jarvis et al.
· 2020
[cited by applicant]
US 20200270617A1
· Finn
· 2020
[cited by examiner]
US 20200270716A1
· Finn
· 2020
[cited by applicant]
US 20240141317A1
· Baltes
· 2024
[cited by applicant]
US 20240141320A1
· Baltes
· 2024
[cited by applicant]
US 20240141321A1
· Baltes
· 2024
[cited by applicant]
US 20240141322A1
· Baltes
· 2024
[cited by applicant]
BR 102014027448A2
· 2015
[cited by applicant]
CA 2906747A1
· 2014
[cited by applicant]
EP 2893025B1
· 2015
[cited by applicant]
EP 3114227A1
· 2017
[cited by applicant]
EP 3122880A2
· 2017
[cited by applicant]
EP 3344771A1
· 2018
[cited by applicant]
EP 3375877A1
· 2018
[cited by applicant]
EP 3426784A1
· 2019
[cited by applicant]
EP 3556858A2
· 2019
[cited by applicant]
EP 3592140A1
· 2020
[cited by applicant]
EP 3080274
· 2020
[cited by applicant]
ES 2653212T3
· 2018
[cited by applicant]
ES 2699848T3
· 2019
[cited by applicant]
ES 2730378T3
· 2019
[cited by applicant]
JP 2020530769A
· 2020
[cited by applicant]
WO 2010097437A1
· 2010
[cited by applicant]
WO 2012051343A1
· 2012
[cited by applicant]
WO 2013044008
· 2013
[cited by applicant]
WO 2013075008A1
· 2013
[cited by applicant]
WO 2013169802A1
· 2013
[cited by applicant]
WO 2014011237A1
· 2014
[cited by applicant]
WO 2014089212
· 2014
[cited by applicant]
WO 2014186585
· 2014
[cited by applicant]
WO 2015017866A1
· 2015
[cited by applicant]
WO 2015089046
· 2015
[cited by applicant]
WO WO2015089351A1
· 2015
[cited by examiner]
WO 2015127439
· 2015
[cited by applicant]
WO 2015153780A1
· 2015
[cited by applicant]
WO 2015173436A1
· 2015
[cited by applicant]
WO 2016073990A2
· 2016
[cited by applicant]
WO 2016109840A2
· 2016
[cited by applicant]
WO 2016161380A1
· 2016
[cited by applicant]
WO 2016172727A1
· 2016
[cited by applicant]
WO 2016182959A8
· 2016
[cited by applicant]
WO 2017048995A1
· 2017
[cited by applicant]
WO 2017123757A1
· 2017
[cited by applicant]
WO 2017155408A1
· 2017
[cited by applicant]
WO 2017158422
· 2017
[cited by applicant]
WO 2018009562A1
· 2018
[cited by applicant]
WO WO2018009534A1
· 2018
[cited by examiner]
WO 2018131551
· 2018
[cited by applicant]
WO 2018195555A1
· 2018
[cited by applicant]
WO 2018197020A1
· 2018
[cited by applicant]
WO 2019005851A1
· 2019
[cited by applicant]
WO 2019092505A1
· 2019
[cited by applicant]
WO 2019113149A1
· 2019
[cited by applicant]
WO 2019118875A1
· 2019
[cited by applicant]
WO 2019157326A1
· 2019
[cited by applicant]
WO 2019157326A2
· 2019
[cited by applicant]
WO 2019178500
· 2019
[cited by applicant]
WO 2019183123A1
· 2019
[cited by applicant]
WO 2019210216A2
· 2019
[cited by applicant]
WO 020082042A2
· 2020
[cited by applicant]
WO 2020081438
· 2020
[cited by applicant]
WO 2020082041A1
· 2020
[cited by applicant]
WO 2020082046A2
· 2020
[cited by applicant]
WO 2020082047A1
· 2020
[cited by applicant]
Intellia Therapeutics, “Q3 2018 Earnings and Corporate Development”, Powerpoint, 23 pages, presented Oct. 31, 2018, 1-23 (Year: 2018).
[cited by examiner]
Blueallele, LLC in connection with PCT/US2019/058857 filed Oct. 30, 2019, “The International Search Report and the Written Opinion of the International Searching Authority, or the Declaration”, 19 pages, mailed Jun. 23,…
[cited by applicant]
Robert, Francois, “Bidirectional terminators: an underestimated aspect of gene regulation”, Curr Genet, vol. 64, pp. 389-391, 2018.
[cited by applicant]
Ouyang et al., “CRISPR/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells”, vol. 27, No. 11, pp. 756-770, 2018.
[cited by applicant]
Blueallele, LLC in connection with PCTUS2019/056083 filed Oct. 14, 2019, “The International Search Report and the Written Opinion of the International Searching Authority, or the Declaration”, 21 pages, mailed Dec. 19, …
[cited by applicant]
Friedel et al., “Gene targeting using a promoterless gene trap vector (“targeted trapping”) is an efficient method to mutate a large fraction of genes”, PNAS, vol. 102, No. 37, pp. 13188-13193, Sep. 13, 2005.
[cited by applicant]
Gilles et al., “Efficient CRISPR-mediated gene targeting and transgene replacement in the beetle
[cited by applicant]
Hahm et al., “Construction of retroviral vectors with enhanced efficiency oftransgene expression”, Journal of Virological Methods, vol. 121, pp. 127-136, May 27, 2004.
[cited by applicant]
Hildinger et al., “Design of 5′ Untranslated Sequences in Retroviral Vectors Developed for Medical Use”, Journal of Virology, vol. 73, No. 5, pp. 4083-4089, May 1999.
[cited by applicant]
Intellia Therapeutics, “Q3 2018 Earnings and Corporate Development”, Powerpoint, 23 pages, presented Oct. 31, 2018.
[cited by applicant]
Ruan et al., “Highly efficient CRISPR/Cas9-mediated transgene knockin at the H11 locus in pigs”, Scientific Reports, 10 pages, Sep. 18, 2015.
[cited by applicant]
Suzuki et al., “In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration”, Nature, vol. 540, 24 pages, Dec. 1, 2016.
[cited by applicant]
Uno et al., “CRISPR/Cas9-induced transgene insertion and telomere-associated truncation of a single human chromosome for chromosome engineering in CHO and A9 cells”, Scientific Reports, 10 pages, Oct. 6, 2017.
[cited by applicant]
Yao et al., “Homology-mediated end joining-based targeted integration using CRISPR/Cas9”, Cell Research, vol. 27, pp. 801-814, Apr. 6, 2017.
[cited by applicant]
Sheng et al Canadian Journal of Microbiology, 445-454 (Year: 2014).
[cited by applicant]
Ryu et al Plant Molecular Biology 54: 489-502 (Year: 2004).
[cited by applicant]
Senis et al Nucleic acid Res. , 45(1), e3 (Year: 2016).
[cited by applicant]
Kaiser Science, 317, 580 (Year: 2007).
[cited by applicant]
Frank et al N. Engl. J Med. Jul 9;361 (2): 161-9 (Year: 2009).
[cited by applicant]
Edelstein Journal Gene Med., 597-602 (Year: 2004).
[cited by applicant]
High Nature, 435, 577-579 (Year: 2005).
[cited by applicant]
Ramirez Nature Methods, 5(5): 374-375 (Year: 2008).
[cited by applicant]
Li Nature, Jul. 14,, 475, 7355, 217-221 (Year: 2011).
[cited by applicant]
Christian Genetics, 757-761 (Year: 2010).
[cited by applicant]
Hauschild PNAS, 108( 29), 12013-12017 (Year: 2011).
[cited by applicant]
Hsu et al Nat Biotechnology. Sep;31 (9):827-32 (Year: 2013).
[cited by applicant]
Lee et al., (Drug Discovery Today: Disease Models, vol. 20, 13-20 (Year: 2016).
[cited by applicant]
Kosicki et al Nature Biotechnology, 36, 765-771 (Year: 2018).
[cited by applicant]
Robert et al Curr Genetics, 64(2):389-391 (Year: 2018).
[cited by applicant]
Cox et al , Nature Medicine 21 (2), 121-13 (Year: 2015).
[cited by applicant]
Kuscu et al Nature biotechnology, 32(7), 677 (Year: 2014).
[cited by applicant]
Kleinstiver Nature, 523, 481-485 (Year: 2015).
[cited by applicant]
Pluta et al. (Acta Biochimica Polonica. Nov. 23, 2009. 54(4): 531-595) (Year: 2009).
[cited by applicant]
Kurosaki et al. (Journal of Human Genetics (2011) 56, 727-733). (Year: 2011).
[cited by applicant]
Great Britain Search Report, issued Feb. 8, 2023, in connection with Great Britain Application No. GB2300487.2, 1 page.
[cited by applicant]
Ohmori et al. “CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice”, Sci Rep, Jun. 2, 20173, vol. 7, No. 1, article No. 4159 (11 pages).
[cited by applicant]
Finn, Jonathan Ph.D. “Supra-therapeutic levels of transgene expression achieved in vivo by CRISPR/Cas9 mediated targeted gene insertion”, 26thAnnual Congress of the European Society of Cell Therapy, Oct. 18, 2018, (14 p…
[cited by applicant]
Yew et al. Human Gene Therapy 8:575-584 (Year 1997).
[cited by applicant]
Aschauer et al., Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Stereotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain, PLoS One Sep. 27, 2013;8(9):e76310.
[cited by applicant]
Auer et al., CRISPR/Cas9-mediated conversion of eGFP- into Gal4-transgenic lines in zebrafish, Nat Protoc Dec. 2014;9(12):2823-40.
[cited by applicant]
Auer et al., Highly efficient CRISPR/Cas9-mediated knock-in zebrafish by homology-independent DNA-repair, Genome Res Jan. 2014,24(1):142-53.
[cited by applicant]
Barket et al., Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice, J Gene Med Jun. 2009;11(6):486-497.
[cited by applicant]
Bell et al., Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates., Mol Genet Metab Nov. 2011;104(3):395-403.
[cited by applicant]
Bill et al., Genomic DNA double-strand breaks are targets for hepadnaviral DNA interogation, Proc Natl Acad Sci U S A Jul. 27, 2004;101(30):11135-40.
[cited by applicant]
Brocchieri and Karlin Protein length in eukaryotic and prokaryotic proteomes, Nucleic Acids Res Jun. 10, 2005;33(10):3390-400.
[cited by applicant]
Chen et al., Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII, Sci Rep Nov. 14, 2019;9(1):16838.
[cited by applicant]
Chu et al., Efficient generation of Rosa26 knock-in mice using CRISPR/Cas9 in CB57BL/6 zygotes, BMC Biotechnol Jan. 16, 2016;16:4.
[cited by applicant]
Chuah et al., Liver-Specific Transcriptional Modules Identified Genome-Wide In Silico Analysis Enable Efficient Gene Therapy in Mice and Non-Human Primates, Mol Ther Sep. 2014;22(9):1605-13.
[cited by applicant]
Cui et al., A CRISPR/Cas9-Mediated, Homology-Independent Tool Developed for Targeted Genome Integration in Yarrowia lipolytica, Appl Environ Microbiol Feb. 26, 2021;87(6):e02666-20.
[cited by applicant]
De Caneva et al., Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases, JCI Insight Aug. 8, 2019;4(15):e128863.
[cited by applicant]
Diao et al., Plug-and-Play Genetic Access to Drosophila Cell Types using Exchangeable Exon Cassettes, Cell Rep Mar. 3, 2015;10(8):1410-21.
[cited by applicant]
Finn et al., A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing , Cell Rep (2018) Feb. 27;22(9):2227-2235.
[cited by applicant]
Friedland et al., Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications, Genome Biol Nov. 2, 20154:16:257.
[cited by applicant]
Gabriel et al., An unbiased genome-wide analysis of zinc-finger nuclease specificity, Nat Biotechnol Aug. 7, 2011;29(9):816-23.
[cited by applicant]
Geisinger et al., In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining, Nucleic Acids Res May 5, 2016;44(8):e76.
[cited by applicant]
Guan et al., CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse , EMBO Mol Med May 2, 2016;8(5):477-88.
[cited by applicant]
Hashimoto et al., Electroporation enables the efficient mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas9-based genome editing, Sci Rep Aug. 5, 2015:5:12658.
[cited by applicant]
He et al., Knock-in of large reporter genes in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair, Nucleic Acids Res May 19, 2016;44(9):e85.
[cited by applicant]
Hocquemiller et al., Adeno-Associated Virus-Based Gene Therapy for CNS Diseases, Hum Gene Ther Jul. 2016;27(7):478-96.
[cited by applicant]
Hu et al., In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa, Invest Ophthalmol Vis Sci Apr. 9, 2020;61(4):31.
[cited by applicant]
Hung et al., AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo, Invest Ophthalmol Vis Sci Jun. 1, 2016;57(7):3470-6.
[cited by applicant]
Ibraheim et al., All-in-One Adeno-associated Virus Delivery and Genome Editing by Neisseria meningitidis Cas9 in vivo, Genome Biol Sep. 19, 2018;19(1):137.
[cited by applicant]
Jarrett et al., Somatic editing of LdIr with AAV-CRISPR is an efficient tool for atherosclerosis research, Arterioscler Thromb Vasc Biol Sep. 2018;38(9):1997-2006.
[cited by applicant]
Jarrett et al., Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease, Sci Rep Mar. 16, 2017:7:44624.
[cited by applicant]
Jiang et al., A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo, Cell Res Mar. 2017;27(3):440-443.
[cited by applicant]
Kawabe et al., Targeted knock-in of an scFv-Fc antibody gene into the hprt locus of Chinese hamster ovary cells using CRISPR/Cas9 and CRIS-PITCh systems , J Biosci Bioeng May 2018;125(5):599-605.
[cited by applicant]
Jul. 8, 2024, Exhibit 4, Intellia Corporate Overview, Nov. 2022, 92 pages.
[cited by applicant]
Jul. 8, 2024, Exhibit 5, Feb. 22, 2024 Intellia 10-K, 24 pages.
[cited by applicant]
Jul. 8, 2024, Exhibit 6, ESGCT Presentation, 16 pages.
[cited by applicant]
Jul. 8, 2024, Exhibit 7, Oct. 2021 Intellia Corp Overview, 36 pages.
[cited by applicant]
Jul. 8, 2024, Exhibit 9, Civil Cover Sheet, 2 pages.
[cited by applicant]
Jul. 8, 2024, Plaintiff's Complaint for Patent Infringement, 19 pages.
[cited by applicant]
Sep. 12, 2024, Declaration re [20] Motion to Dismiss for Failure to State a Claim (of Daniel Hemming), 5 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit A, Jun. 26, 2021 Intellia Press Release, 6 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit B, 2018 ESGCT Stats, 3 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit C, 2018 ESGCT Abstract Book, 186 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit D, Oct. 18, 2018 Intellia Press Release, 4 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit E, REGN Phase 1 trial—clinicaltrials.gov, 18 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit F, Jul. 30, 2024 Intellia Press Release, 3 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit G, Blueallele Corporation—De Certified Docs, 8 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit H, Baltes 2021 CV, 5 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit J, Kuleon Bio—Forest Quote, 5 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit K, CMC-Information-Human-Gene-Therapy-IND-Applications_Jan_2020, 57 pages.
[cited by applicant]
Sep. 12, 2024, Exhibit L, Human-Gene-Therapy-for-Hemophilia_Jan_2020)(Smith, Rodger), 18 pages.
[cited by applicant]
Sep. 23, 2024, D25 so Ordered Stip for EOT to Resp to MTD or Amd Complaint, 1 page.
[cited by applicant]
Oct. 16, 2024, D26 Order—Oral Arg on MTD, 1 page.
[cited by applicant]
Oct. 23, 2024, D27 BlueAllele Ans Brief IOT MTD, 23 pages.
[cited by applicant]
Oct. 28, 2024, D28 Stip and Prop Order for EOT, 2 pages.
[cited by applicant]
Oct. 28, 2024, D29 So Ordered Stip and Order for EOT, 2 pages.
[cited by applicant]
Nov. 8, 2024, D30 Def's Reply Brief ISO MTD, 16 pages.
[cited by applicant]
Nov. 19, 2024, D31 Def's Mot for Exempption of Persons fr Standing order re Personal Electronics, 3 pages.
[cited by applicant]
Nov. 19, 2024, D32 SO Ordered D31 Mot for Exemption of Persons fr Standing Order re Personal Electronic Devices, 3 pages.
[cited by applicant]
Nov. 19, 2024, D33 Pltf's NOA of Warren Mabey, 2 pages.
[cited by applicant]
Dec. 9, 2024, D035 Memo Opinion, 8 pages.
[cited by applicant]
Dec. 9, 2024, D036 Order Denying Def's MTD, 1 page.
[cited by applicant]
Dec. 16, 2024, D038 Order granting D37 Stip for EOT and Commencing Discovery, 2 pages.
[cited by applicant]
Dec. 16, 2024, D37 Stip for EOT and Commence Discovery, 2 pages.
[cited by applicant]
Dec. 20, 2024, D39 NOS of Pltfs 1st Set of Discovery Reqs, 2 pages.
[cited by applicant]
Dec. 23, 2024, D40 NOS of Def's 1st Set of RPFs and Rogs, 3 pages.
[cited by applicant]
Jan. 6, 2025, Exhibit 2, Q3 2018 Earnings and Corporate Developments, Oct. 31, 2018, 24 pages.
[cited by applicant]
Jan. 6, 2025, Exhibit 3, Calyxt names Joseph B. Saluri as General Counsel & EVP, Corporate Development, 3 pages.
[cited by applicant]
Jan. 6, 2025, Exhibit 4, Second declaration of Nicholas J. Baltes, PH.D., 22 pages.
[cited by applicant]
Jan. 6, 2025, Exhibit 5, Transformative Technology for Correcting Gene Function in vivo, 5 pages.
[cited by applicant]
Jan. 6, 2025, Exhibit 1, Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments, Oct. 31, 2018, 6 pages.
[cited by applicant]
Jan. 6, 2025, Exhibit 8, BlueAllele Presentation Apr. 2022, 13 pages.
[cited by applicant]
Jan. 6, 2025, Exhibit 9, Our Pipeline—Intellia Therapeutics, 5 pages.
[cited by applicant]
Jan. 6, 2025, Intellia's Counterclaims, Answer, and Affirmative Defenses To Blueallele's Complaint, 67 pages.
[cited by applicant]
Jan. 17, 2025, Stipulation and [Proposed] Order To Extend Time and Proceed With Discovery From Blueallele, 2 pages.
[cited by applicant]
Jan. 21, 2025, D43 Order setting Initial Pretrial videoconf for Feb. 21, 2025, 8 pages.
[cited by applicant]
Jan. 21, 2025, D44 Order not approving Stip for EOT re D42, 1 page.
[cited by applicant]
Jan. 27, 2025, [Proposed] Order Granting Plaintiff's Motion To Dismiss Defendant's Counterclaims, 1 page.
[cited by applicant]
Jan. 27, 2025, Certification Regarding Motion To Dismiss Counterclaims Pursuant To Policies and Procedures of Judge John F. Murphy, 2 pages.
[cited by applicant]
Jan. 27, 2025, Confirmation receipt for U.S. Appl. No. 62/747,393, Exhibit 3, 119 pages.
[cited by applicant]
Jan. 27, 2025, Declaration of Jonathan A. Bell in Support of Plaintiff's Motion To Dismiss Defendant's Counterclaims, 2 pages.
[cited by applicant]
Jan. 27, 2025, Exhibit 1, Office action summary, 15 pages.
[cited by applicant]
Jan. 27, 2025, Exhibit 2, Bloomberg News Article, 3 pages.
[cited by applicant]
Yang et al., A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice, Nat Biotechnol Mar. 2016;34(3):334-8.
[cited by applicant]
Yao et al., Homology-mediated end joining-based targeted integration using CRISPR/Cas9, Cell Res Jun. 2017;27(6):801-814.
[cited by applicant]
Yao et al., 2 CRISPR/Cas9—Mediated Precise Targeted Integration In Vivo Using a Double Cut Donor with Short Homology Arms, EBioMedicine Jun. 2017:20:19-26.
[cited by applicant]
Yin et al., Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype, Nat Biotechnol Jun. 2014;32(6):551-3.
[cited by applicant]
Yin et al., Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo, Nat Biotechnol Mar. 2016;34(3):328-33.
[cited by applicant]
Yu et al., Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice, Nat Commun Mar. 14, 2017:8:14716.
[cited by applicant]
Zhang et al., Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse, Genome Biol Dec. 16, 2019;20(1):276.
[cited by applicant]
Zhang et al., Large genomic fragment deletions and insertions in mouse using CRISPR/Cas9, PLoS One Mar. 24, 2015;10(3):e0120396.
[cited by applicant]
Zhao et al., In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia, Circulation Jan. 7, 2020;141(1):67-79.
[cited by applicant]
US Patent Office, TPS US20200289628, 32 pages.
[cited by applicant]
US Patent Office, TPS US20200270618, 28 pages.
[cited by applicant]
US Patent Office, TPS US20200270617, 35 pages.
[cited by applicant]
US Patent Office, TPS US20200268906, 27 pages.
[cited by applicant]
Eu Patent Office, TPO EP3867376, 14 pages.
[cited by applicant]
Eu Patent Office, TPO EP3867378, 8 pages.
[cited by applicant]
EU Patent Office, TPO EP3867380, 12 pages.
[cited by applicant]
EU Patent Office, TPO EP3867381, 10 pages.
[cited by applicant]
GB Patent Office, Examination Report 1, 4 pages.
[cited by applicant]
GB Patent Office, Response 1, 3 pages.
[cited by applicant]
GB Patent Office, Notification of Grant 1, 2 pages.
[cited by applicant]
GB Patent Office, Notification of Grant 2, 2 pages.
[cited by applicant]
DE Patent Office, Examination Report 1, 6 pages.
[cited by applicant]
DE Patent Office, Response 1, 7 pages.
[cited by applicant]
DE Patent Office, Examination Report 2, 3 pages.
[cited by applicant]
DE Patent Office, Response 2, 2 pages.
[cited by applicant]
DE Patent Office, Notification of Grant, 7 pages.
[cited by applicant]
JP Patent Office, Examination Report 1, 6 pages.
[cited by applicant]
JP Patent Office, Response 1, 4 pages.
[cited by applicant]
JP Patent Office, Notification of Grant, 4 pages.
[cited by applicant]
NZ Patent Office, Examination Report 1, 4 pages.
[cited by applicant]
NZ Patent Office, Response 1, 3 pages.
[cited by applicant]
NZ Patent Office, Notification of Grant, 1 page.
[cited by applicant]
AU Patent Office, Examination Report 1, 2 pages.
[cited by applicant]
AU Patent Office, Response 1, 10 pages.
[cited by applicant]
AU Patent Office, Notification of Grant, 3 pages.
[cited by applicant]
EA Patent Office, Examination Report 1, 2 pages.
[cited by applicant]
EA Patent Office, Response 1, 5 pages.
[cited by applicant]
EA Patent Office, Examination Report 2, 3 pages.
[cited by applicant]
EA Patent Office, Response 2, 4 pages.
[cited by applicant]
EA Patent Office, Notification of Grant, 2 pages.
[cited by applicant]
EU Patent Office, Examination Report 1, 4 pages.
[cited by applicant]
EU Patent Office, Response 1, 4 pages.
[cited by applicant]
EU Patent Office, Examination Report 2, 5 pages.
[cited by applicant]
EU Patent Office, Response 2, 5 pages.
[cited by applicant]
EU Patent Office, Examination Report 3, 4 pages.
[cited by applicant]
EU Patent Office, Response 3, 5 pages.
[cited by applicant]
EU Patent Office, Examination Report 4, 3 pages.
[cited by applicant]
EU Patent Office, Response 4, 4 pages.
[cited by applicant]
EU Patent Office, Examination Report 5, 2 pages.
[cited by applicant]
EU Patent Office, Response 5, 10 pages.
[cited by applicant]
Jan. 27, 2025, Plaintiff's Motion To Dismiss Defendant's Counterclaims, 2 pages.
[cited by applicant]
Jan. 27, 2025, Plaintiff's Opening Brief in Support of Its Motion To Dismiss Defendant's Counterclaims, 27 pages.
[cited by applicant]
Feb. 7, 2025, D051 NOS of Intellia's Initial Discls, 3 pages.
[cited by applicant]
Feb. 7, 2025, D052 NOS of BlueAllele Initial's Discls, 2 pages.
[cited by applicant]
Feb. 10, 2025, D053 Intellia's Ans Brief Iot Mtd, 27 pages.
[cited by applicant]
Feb. 14, 2025, D054 Jt Rule 26(f) Report, 13 pages.
[cited by applicant]
Feb. 14, 2025, D054-01 Prop Scheduling Order, 14 pages.
[cited by applicant]
Feb. 18, 2025, D055 Reply Brief ISO MTD CCs, 15 pages.
[cited by applicant]
Feb. 18, 2025, D056 Request for Oral Argument, 2 pages.
[cited by applicant]
Feb. 19, 2025, D057 Mot and Order for PHV_Nina Elder, 2 pages.
[cited by applicant]
Feb. 24, 2025, D061 Order re Pltfs MTD is Granted in part and Denied in part, 1 page.
[cited by applicant]
Feb. 24, 2025, D62 Sched Order, 12 pages.
[cited by applicant]
Feb. 25, 2025, D63 Not of Withdrawal_Finn, 2 pages.
[cited by applicant]
Feb. 27, 2025, D067 Stip for EOT to file Prop PO, 1 page.
[cited by applicant]
Feb. 27, 2025, D64 Mot for PHV_Jennifer Esch and Manuela Burek, 4 pages.
[cited by applicant]
Feb. 28, 2025, D068 Order Granting D067 Stip for EOT to File PO, 1 page.
[cited by applicant]
Mar. 10, 2025, D071 Unopposed Mot to Extend DL to Ans CCs, 5 pages.
[cited by applicant]
Mar. 10, 2025, D071-01 Prop Order Granting Unopposed Mot for EOT, 1 page.
[cited by applicant]
Mar. 10, 2025, D072 Order Granting Unopposed Mot for EOT to Answer Counterclaims, 1 page.
[cited by applicant]
Mar. 10, 2025, D073 BlueAllele's Ans to Cntrclaim, 45 pages.
[cited by applicant]
Mar. 14, 2025, D074 Stip for EOT to File Proposed Protective Order, 2 pages.
[cited by applicant]
Mar. 17, 2025, D075 Order Granting D74 Stip for EOT to File Prop PO, 2 pages.
[cited by applicant]
Mar. 21, 2025, D076 NOS of Pltf's Para 3 Discls, 3 pages.
[cited by applicant]
Mar. 21, 2025, D078 Jt Ltr to Jdg Murphy re Protective Order Dispute, 8 pages.
[cited by applicant]
Mar. 21, 2025, D79 NOS of Pltf's 2nd Set of Discovery, 3 pages.
[cited by applicant]
Mar. 21, 2025, D80 Pltf's Mot for Admission PHV_Rafferty, 2 pages.
[cited by applicant]
Mar. 25, 2025, D078-01 Ex A to Jt Ltr to Jdg Murphy re Protective Order Dispute, 28 pages.
[cited by applicant]
Mar. 25, 2025, D078-02 Ex B to Jt Ltr to Jdg Murphy re Protective Order Dispute, 5 pages.
[cited by applicant]
Mar. 24, 2025, D82 Order Granting D80 Mot for Admission PHV_Rafferty, 1 page.
[cited by applicant]
Robert F. Bidirectional terminators: an underestimated aspect of gene regulation. Curr Genet. Apr. 2018;64(2):389-391.
[cited by applicant]
Sandford, Andrew J. “Alpha-1 Antritrypsin Mutations: Is One Too Many?” American Thoracic Society, Dec. 6, 2019 (2 pages).
[cited by applicant]
EU Patent Office, Notification of Grant, 5 pages.
[cited by applicant]
EU Patent Office, Third Party Observations Combined, 32 pages.
[cited by applicant]
EU Patent Office, Examination Report 6, 2 pages.
[cited by applicant]
Notification of Grant foreign counterpart German Patent 11 2019 005 166 on Sep. 16, 2024 with English translation. (14 pages).
[cited by applicant]
Examination Report issued on Mar. 10, 2025 in Foreign Counterpart Australian Patent Application No. 2023202878 (3 pages).
[cited by applicant]
Stipulated Protective Order issued Mar. 24, 2025 (27 pages).
[cited by applicant]
Notice of Service Intellia's Core Technical Document Production issued Apr. 4, 2025 (4 pages).
[cited by applicant]
Notice of Entry of Appearance on Apr. 4, 2025 of Q. Claire Xue, Ph.D. (2 pages).
[cited by applicant]
Kong et al., Self-complementary AAV5 Vector Facilitates Quicker Transgene Expression in Photoreceptor and Retinal Pigment Epithelial Cells of Normal Mouse, Exp Eye Res. Feb. 4, 2010;90(5):546-554.
[cited by applicant]
Kramer The structure and function of proteins involved in mammalian pre-mRNA splicing , Annu Rev Biochem 1996:65:367-409.
[cited by applicant]
Laoharawee et al., Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing , Mol Ther (2018) Apr 4;26(4):1127-1136.
[cited by applicant]
Laoharawee et al., Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer, Hum Gene Ther Aug. 2017;28(8):626-638.
[cited by applicant]
Lee et al., In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector, Mol Ther Nucleic Acids Mar. 21, 2023:32:161-172.
[cited by applicant]
Lee et al., Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair , Nat Biomed Eng 2017:1:889-901.
[cited by applicant]
Lee et al., A gene-specific T2A-GAL4 library for Drosophila, Elife Mar. 22, 2018:7:e35574.
[cited by applicant]
Li et al., AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9, Mol Ther Jun. 3, 2020;28(6):1432-1441.
[cited by applicant]
Li et al., Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9, Front Immunol Sep. 11, 2018;9:2080.
[cited by applicant]
Li et al., Intron targeting-mediated and endogenous gene integrity-maintaining knockin in zebrafish using the CRISPR/Cas9 system , Cell Res May 2015;25(5):634-7.
[cited by applicant]
Li et al., In vivo genome editing restores haemostasis in a mouse model of haemophilia , Nature Jun. 26, 2011;475(7355):217-21.
[cited by applicant]
Lin et al., Promiscuous patching of broken chromosomes in mammalian cells with extrachromosomal DNA , Nucleic Acids Res Oct. 1, 2001;29(19):3975-81.
[cited by applicant]
Loser et al., Reactivation of the Previously Silenced Cytomegalovirus Major Immediate-Early Promoter in the Mouse Liver: Involvement of NFηB, J Virol Jan. 1998;72(1):180-190.
[cited by applicant]
Mao et al., CRISPR/Cas9-mediated efficient and precise targeted integration of donor DNA harboring double cleavage sites in Xenopus tropicalis , FASEB J Jun. 13, 2018:fj201800093.
[cited by applicant]
Mersmann et al., Aspartoacylase-LacZ Knockin Mice: An Engineered Model of Canavan Disease, PLoS One 2011;6(5):e20336.
[cited by applicant]
Miller et al., Adeno-associated virus vectors integrate at chromosome breakage sites, Nat Genet Jul. 2004;36(7):767-73.
[cited by applicant]
Miller et al., Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA, Angew Chem Int Ed Engl Jan. 19, 2017;56(4):1059-1063.
[cited by applicant]
Min et al., CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells, Sci Adv Mar. 6, 2019;5(3):eaav4324.
[cited by applicant]
Nakade et al., Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9, Nat Commun Nov. 20, 2014:5:5560.
[cited by applicant]
Nelson et al., In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy, Science Jan. 22, 2016;351(6271):403-7.
[cited by applicant]
Ohmori et al., CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice , Sci Rep Jun. 23, 2017;7(1):4159.
[cited by applicant]
Orlando et al., Zinc-finger nuclease-driven targeted integration into mammalian genomes using donors with limited chromosomal homology, Nucleic Acids Res Aug. 2010;38(15):e152.
[cited by applicant]
Ou et al., ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome, Mol Ther Jan. 2, 2019;27(1):178-187.
[cited by applicant]
Petrkova et al., Characterization of a Dmd EGFP reporter mouse as a tool to investigate dystopian expression, Skelet Muscle Jul. 5, 2016;6:25.
[cited by applicant]
Platt et al., CRISPR-Cas9 knockin mice for genome editing and cancer modeling, Cell Oct. 9, 2014;159(2):440-55.
[cited by applicant]
Qin et al., Efficient CRISPR/Cas9-Mediated Genome Editing in Mice by Zygote Electroporation of Nuclease, Genetics Jun. 2015;200(2):432-30.
[cited by applicant]
Roy et al., Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery, Int J Parm Jan. 2, 2003;250(1):25-33.
[cited by applicant]
Sakuma et al., MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems, Nat Protoc Jan. 2016;11(1):118-33.
[cited by applicant]
Sarra et al., Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus, Vision Res Feb. 2002;42(4)541-9.
[cited by applicant]
Sharma et al., In vivo genome editing of the albumin locus as a platform for protein replacement therapy., Blood (2015) 126, 1777-1784.
[cited by applicant]
Shinmyo et al., CRISPR/Cas9-mediated gene knockout in the mouse brain using in utero electroporation, Sci Rep Feb. 9, 2016;6:20611.
[cited by applicant]
Singh et al., Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9, Mol Ther May 2, 2018;26(5):1241-1254.
[cited by applicant]
Stephens et al., Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9, Gene Ther Apr. 2018;25(2):139-156.
[cited by applicant]
Swartz et al., Sparking new frontiers: using in vivo electroporation for genetic manipulations, Dev Biol May 1, 2001;233(1):13-21.
[cited by applicant]
Tabebordbar et al., In vivo gene editing in dystrophic mouse muscle and muscle stem cells, Science. Dec. 31, 2015;351(6271):407-411.
[cited by applicant]
Talas et al., A convenient method to pre-screen candidate guide RNAs for CRISPR/Cas9 gene editing by NHEJ-mediated integration of a ‘self-cleaving’ GFP-expression plasmid, DNA Res Dec. 1, 2017;24(6):609-621.
[cited by applicant]
Tiessen et al., Mathematical modeling and comparison of protein size distribution in different plant, animal, fungal and microbial species reveals a negative correlation between protein size and protein number, thus pro…
[cited by applicant]
TIPANEE Validation of miR-20a as a Tumor Suppressor Gene in Liver Carcinoma Using Hepatocyte-Specific Hyperactive piggyBac Transposons, Mol Ther Nucleic Acids Mar. 6, 2020:19:1309-1329.
[cited by applicant]
Venkatesh et al., Retinal Gene Delivery by rAAV and DNA Electroporation, Curr Protoc Microbiol 2013:Chapter 14:Unit 14D.
[cited by applicant]
Wang et al., Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids, Mol Ther Oct. 27, 2015;23(12):1877-1887.
[cited by applicant]
Wang et al., CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice, Mol Ther Methods Clin Dev Jun. 30, 2020:18:520-531.
[cited by applicant]
Wang et al., A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency, Sci Adv Feb. 12, 2020;6(7):eaax5701.
[cited by applicant]
Wang et al., Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening, Sci Adv Feb. 28, 2018;4(2):eaao5508.
[cited by applicant]
Wang et al., Systematic evaluation of CRISPR-Cas systems reveals design principles for genome editing in human cells, Genome Biol. (2018) May 29;19:62.
[cited by applicant]
Wang et al., Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors , Nat Biotechnol Feb. 2015;33(2):175-8.
[cited by applicant]
Wang et al., Large genomic fragment deletion and functional gene cassette knock-in via Cas9 protein mediated genome editing in one-cell rodent embryos , Sci Rep Dec. 1, 2015:5:17517.
[cited by applicant]
Willems et al., Orange: A CRISPR/Cas9-based genome editing toolbox for epitope tagging of endogenous proteins in neurons, PLoS Biol Apr. 10, 2020;18(4):e3000665.
[cited by applicant]
Xiong et al., AAV cis-regulatory sequences are correlated with ocular toxicity, Proc Natl Acad Sci U S A Mar. 19, 2019;116(12):5785-5794.
[cited by applicant]
Xu et al., CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice, Mol Ther Mar. 2016;24(3):564-9.
[cited by applicant]
Xue et al., CRISPR-mediated direct mutation of cancer genes in the mouse liver, Nature Oct. 16, 2014;514(7522):380-4.
[cited by applicant]